Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF (FTC/TDF) for treatment of chronic hepatitis B (CHB) in patients with persistent viral replication receiving adef…
T Berg, B Möller, G Gerken, R Zachoval, U Spengler, H Hartmann, A Snow-Lampart, D Oldach, J Sorbel, K Borroto-Esoda, D Frederick, F Rousseau · Zeitschrift für Gastroenterologie · 2009 · Heft 09
Bibliografische Angaben
Zusammenfassung
Introduction: This trial compared TDF monotherapy versus combination FTC/TDF therapy in CHB patients who had incomplete virologic response after receiving adefovir dipivoxil (ADV) for at least 6 months. In both blinded treatment arms, patients were permitted to change to open-label FTC/TDF after 24 weeks (W) if persistent viremia >400 copies/mL was confirmed. Methodology: Entry criteria and baseline demographics/disease characteristics have been reported previously (Berg, et al., 2008 EASL). Among the 105 patients randomized and treated with TDF (N=53) or FTC/TDF (N=52) in this ongoing study, 57% had prior lamiv…
